GlassScriptPhysician profile
Ryan J Rodela
NPI 1598262438
$13,654.29
in general payments reported to CMS, 2019-2025
32 companies · $2,934 in 2025
The $2,934 reported for 2025 was more than what 89% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $531 · 2022: $7,663 · 2023: $1,720 · 2024: $807 · 2025: $2,934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,768 · Travel and Lodging: $2,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,767.82 |
| Travel and Lodging | $2,692.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $4,486.21 | 2021-2025 | Ortholoc 2 Lapifuse, Variax, Augment Injectable |
| Crossroads Orthopedics, LLC | $3,815.28 | 2022 | |
| Arthrex, INC. | $3,067.33 | 2022 | |
| Medical Device Business Services, INC. | $324.99 | 2021 | |
| Smith+Nephew, INC. | $305.62 | 2023-2025 | Collagenase Santyl, Pico, Renasys Touch |
| Orthofix Medical, INC. | $265.81 | 2023-2025 | Physio-Stim |
| Tactile Systems Technology INC | $249.26 | 2022-2024 | Entre Plus, Flexitouch Plus |
| Paratek Pharmaceuticals, INC. | $137.43 | 2022-2025 | Nuzyra |
| Flower Orthopedics Coporation | $127.59 | 2022 | |
| Kerecis Limited | $111.71 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Surgiclose, Kerecis Omega3 Marigen |
| Polynovo North America LLC | $88.66 | 2024-2025 | Novosorb Btm |
| Depuy Synthes Sales INC. | $84.65 | 2025 | Hammerlock, Motoband, Foot Osteotomy Wedge System |
| Organogenesis INC. | $65.45 | 2023-2025 | Puraply, Puraply Wound Matrix |
| Solventum Corporation | $52.66 | 2024 | V.A.C. Veraflo Cleanse Choice, Prevena, Activ.A.C. |
| Averitas Pharma INC. | $44.39 | 2023-2025 | Qutenza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $44.35 | 2024 | Intellis Adaptivestim |
| Boston Scientific Corporation | $40.28 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Treace Medical Concepts, INC. | $37.15 | 2023 | |
| Triad Life Sciences INC. | $34.55 | 2022 | |
| Zimmer Biomet Holdings, INC. | $33.07 | 2021 | |
| Polymedics Innovations INC. | $30.02 | 2025 | |
| Access Pro Medical, LLC | $28.55 | 2025 | Matriderm |
| Paragon 28, INC. | $24.85 | 2022-2023 | Plating Portfolio |
| Dynasplint Systems INC. | $21.17 | 2025 | Dynasplint |
| Aroa Biosurgery Incorporated | $20.33 | 2025 | |
| Novastep INC. | $19.11 | 2022 | |
| Kci USA, INC. | $17.46 | 2023 | Prevena, V.A.C. Dermatac, V.A.C. Veraflo Cleanse Choice |
| Abbott Laboratories | $16.86 | 2025 | Proclaim |
| Convatec INC. | $16.34 | 2024 | |
| Nabriva Therapeutics, Plc | $15.90 | 2022 | |
| Integra Lifesciences Corporation | $15.26 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Rodela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.